$ADGM

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed in Adagio Medical Holdings, Inc.’s (the “Company”) Current Report on Form 8-K filed on September 23, 2026, in connection with its process to explore strategic alternatives, the Company notified the holders

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value Company Continues to Advance PMA Application for vCLAS Ventricular Ablation System While Board Evaluates Full Range of Strategic Options ​ LAGUNA HILLS, CA, September 23, 2026 – Adagio

Adagio Medical announced study results for its vClas Ultra cryoablation system, with the first patient treated by Dr. Roderick Tung. The study aims to support FDA approval for the first-generation device. Shares of Adagio (ADGM) were trading at 47 cents with a market cap of $10.6 million.

Adagio Medical (ADGM) announced the first patient treated in its IDE study for the next-gen vCLAS Ultra System, designed for ventricular tachycardia (VT). The study aims to support a PMA supplement for the FDA. The system showed improved maneuverability and reduced ablation time in pre-clinical data. The company is focused on demonstrating the system's potential for faster, more efficient VT ablation procedures.

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today anno

Adagio Medical (ADGM) shares rose 21.6% Monday and jumped 22% after hours, after the company said its next-generation vCLAS Ultra ULTA system treated its first patient at the University of Pennsylvania. Adagio also said the FDA approved expanding its FULCRUM-VT IDE trial for the new system and expects first-generation ULTA FDA approval soon.

Adagio Medical Holdings Inc. said it treated the first patient with its next-generation vCLAS Ultra low-temperature ablation system. The company claims it can reach -170°C and cut ablation time by 50% to 75%, shortening procedures by up to 30 minutes versus the prior system. Adagio noted the FDA granted IDE approval in April to expand its FULCRUM-VT trial. Shares rose 19% to 45 cents.

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0002006986 0002006986 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Adagio Medical Holdings submitted a premarket approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System to treat ventricular tachycardia. The filing is supported by six-month Fulcrum-VT IDE trial data: 84% avoided device shocks and 59% had no VT recurrence. Adagio said the system has CE Mark approval; shares trade near $0.75.

Adagio Medical has submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, designed to treat drug-refractory, recurrent ventricular tachycardia. This submission is supported by positive data from the FULCRUM-VT pivotal trial, which showed high acute clinical success and significant improvements in patient outcomes. The company believes this endocardial-only approach could democratize VT ablation and address a major unmet need in treating both ischemic and non-ischemic cardiomyopathy.